Atlas Trials

An Open Phase 3 Study of IV-Globulin SN Inj.10% to Treat Immune Thrombocytopenia

Clinical trial NCT02063789 · COMPLETED

Trial details

NCT number
NCT02063789
Sponsor
Green Cross Corporation
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Immune Thrombocytopenia
Start date
2014-06-01
Primary completion
2016-04-01
Enrollment
81

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.